WATCH NOW: Embracing Targeted Medical Therapies in Neurofibromatosis Type 1

7 Views

07/02/23

Designed to provide a comprehensive and highly interactive overview of novel and emerging data, as well as establish a foundational knowledge base of NF1 as a tumor predisposition syndrome, this activity will begin by identifying hallmark aspects of NF1 natural history and clinical presentation, reviewing updated diagnostic criteria, and describing the genetic etiology and complex pathophysiology that has historically made NF1-associated plexiform neurofibromas (PNs) so difficult to treat. Catalyzed by a dynamic case-based approach, attendees will then be guided through an expert-led exploration of emerging clinical trial data for targeted medical therapies in the setting of NF1-associated tumors, with particular emphasis on toxicity profiles and responsive strategies for anticipating, mitigating, and managing adverse events. Finally, premier clinical experts will examine the pivotal patient-facing role of the pediatric hem/onc nurse in the shifting NF1 treatment paradigm, and real-world patient cases will offer an opportunity to design interprofessional approaches to practical nursing challenges in NF1, including patient assessment, patient/parent education and answering difficult questions, effective emotional support tactics, drug toxicity mitigation tools, and expectation management.